Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long non-coding RNA AP001631.9 (LncRNA-AP001631.9), also called FOXM1-regulated, gastric cancer associated (FRGCA), is a long non-coding RNA whose expression is upregulated in gastric cancer primarily through positive regulation by the transcription factor FOXM1. Increased levels of this lncRNA are correlated with enhanced migration, proliferation, and metastasis capacities of gastric cancer cells in vitro and in mouse models. Knockdown of LncRNA-AP001631.9 suppresses these aggressive phenotypes, suggesting a role in tumor progression and potential as a therapeutic target or biomarker for disease prognosis. No clinically approved drugs target this molecule at present[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long non-coding RNA AP001631.9 (LncRNA-AP001631.9).